Merck Serono's cladribine may become first oral MS drug after positive Phase III results
06 May 2009
Katie McQue
Please Login to read the full article.
06 May 2009
Katie McQue
katie.mcque@informa.com
Merck Serono’s DNA synthesis inhibitor, cladribine, could become the first oral drug for the treatment of relapsing-remitting multiple sclerosis after it demonstrated efficacy in the two-year Phase III study, CLARITY, whose top-line data were announced in January. The detailed findings were...
Please Login to read the full article.
RELATED CONTENT
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
